Submission of bioequivalence test reports to be extended
Published: 2007-04-10 06:57:00
Updated: 2007-04-10 06:57:00
The deadline for the bioequivalence test reports of about 250 drugs may be extended, as a number of pharmaceutical firms have failed to submit their test protocols because of a higher cost and tighter schedule, according to the Korea Food and Drug Administration.
The bio equivalency test repor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
